Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash from Financing Activities (2019 - 2025)

Biodesix's Cash from Financing Activities history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1044.2% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $16.4 million, down 68.46%, while the annual FY2025 figure was $16.4 million, 68.46% down from the prior year.
  • Cash from Financing Activities reached $1.7 million in Q4 2025 per BDSX's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $51.3 million in Q2 2024 to a low of -$4.4 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $7.9 million, with a median of $593500.0 recorded in 2021.
  • The largest YoY upside for Cash from Financing Activities was 7861.51% in 2022 against a maximum downside of 671.97% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$4.4 million in 2021, then skyrocketed by 1059.16% to $41.8 million in 2022, then plummeted by 48.08% to $21.7 million in 2023, then plummeted by 100.83% to -$181000.0 in 2024, then skyrocketed by 1044.2% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Cash from Financing Activities are $1.7 million (Q4 2025), $4.8 million (Q3 2025), and $9.8 million (Q2 2025).